SEATTLE, Nov. 07, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, has begun accepting applications to a Technology Access Program (TAP) for its novel Digital Spatial Profiling technology (formerly referred to as digital IHC). In contrast to the sequential analysis of multi-target immunohistochemistry (IHC) slides, NanoString's Digital Spatial Profiling technology samples analytes on a single slide. This not only shortens experiments and simplifies data analysis, but also provides a higher multiplexing capacity of up to 800 targets and a wider detection range, all with spatial context from Formalin-Fixed, Paraffin-Embedded (FFPE) tissue sections. "To comprehensively understand the tumor and immune response to tumors, it is critical to know not only which targets are expressed, but where they are expressed," said Gordon Mills, M.D., Ph.D., Department Chair, Systems Biology, of The University of Texas MD Anderson Cancer Center. "This complex biology is not readily captured using traditional low-plex immunohistochemistry or techniques such as flow cytometry or mass spectrometry that destroy spatial information. NanoString's technology relies on direct hybridization of RNA oligos and/or barcoded antibodies to detect RNA and protein simultaneously to provide more comprehensive insights into the biology of the tumor microenvironment than has been previously been possible with other techniques." NanoString is expanding access to the Digital Spatial Profiling TAP. Under the program, technology access partners can submit up to 20 FFPE tissue sections and NanoString will perform a high-plex protein spatial profiling assay from a panel of 30 pre-validated antibodies. An assay report along with raw digital data and processed results will be provided back to partners. Researchers interested in participating in NanoString's technology access program for its Digital Spatial Profiling technology should contact us at TAP@nanostring.com. "NanoString aims to help our customers extract the maximum amount of biomarker information out of tumor tissues," said Brad Gray, president and chief executive officer of NanoString Technologies. "The Digital Spatial Profiling technology allows us to multiplex proteins or RNA targets, dramatically increasing the amount of information that a biopharma or academic researcher can get out of a sample. There has been such interest in this capability following our presentation at AACR that we decided to initiate a Technology Access Program."